KR101792875B1 - A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease - Google Patents
A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease Download PDFInfo
- Publication number
- KR101792875B1 KR101792875B1 KR1020150077729A KR20150077729A KR101792875B1 KR 101792875 B1 KR101792875 B1 KR 101792875B1 KR 1020150077729 A KR1020150077729 A KR 1020150077729A KR 20150077729 A KR20150077729 A KR 20150077729A KR 101792875 B1 KR101792875 B1 KR 101792875B1
- Authority
- KR
- South Korea
- Prior art keywords
- red ginseng
- lactic acid
- acid bacteria
- vascular
- composition
- Prior art date
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 62
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 45
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 31
- 239000004310 lactic acid Substances 0.000 title claims abstract description 31
- 241000894006 Bacteria Species 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 208000019553 vascular disease Diseases 0.000 title claims abstract description 19
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims abstract description 21
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims abstract description 21
- 230000036772 blood pressure Effects 0.000 claims abstract description 19
- 102100033902 Endothelin-1 Human genes 0.000 claims abstract description 17
- 101800004490 Endothelin-1 Proteins 0.000 claims abstract description 17
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims abstract description 17
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 235000019137 high fructose diet Nutrition 0.000 claims description 22
- 238000011552 rat model Methods 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010020880 Hypertrophy Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 210000002460 smooth muscle Anatomy 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 abstract description 7
- 231100000216 vascular lesion Toxicity 0.000 abstract description 7
- 210000002376 aorta thoracic Anatomy 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000000855 fermentation Methods 0.000 description 9
- 230000004151 fermentation Effects 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 5
- 229940039696 lactobacillus Drugs 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 239000005526 vasoconstrictor agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000192132 Leuconostoc Species 0.000 description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000035868 Vascular inflammations Diseases 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009329 sexual behaviour Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001256 steam distillation Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022339 Integrin alpha-L Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- -1 mayo Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a composition for preventing, ameliorating or treating vascular diseases, and more particularly, to a composition containing fermented product fermented by mixing red ginseng and lactic acid bacteria as an active ingredient.
The composition according to the present invention is effective in lowering blood pressure, efficacy of alleviating vascular lesions, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) -1 < / RTI > (endothelin-1) expression.
Description
The present invention relates to a composition for preventing, ameliorating or treating vascular diseases, and more particularly, to a composition containing fermented product fermented by mixing red ginseng and lactic acid bacteria as an active ingredient.
The composition according to the present invention is effective in lowering blood pressure, efficacy of alleviating vascular lesions, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) -1 < / RTI > (endothelin-1) expression.
Recently, changes in lifestyle due to industrialization have increased the incidence of vascular diseases such as hypertension, coronary artery disease, atherosclerosis or hyperlipidemia, and the prevalence of metabolic syndrome, which is the primary clinical result of vascular disease, is also increasing .
Due to these vascular diseases, simple edema can cause symptoms such as inflammation of blood vessels and lymph vessels, abnormal shrinkage or swelling of blood vessels, bleeding, and clogging due to thrombosis.
When hyperlipidemia or atherosclerosis occurs, blood pressure increases, which can be a cause of cardiovascular disease and cerebrovascular disease. In addition, diabetes mellitus and liver disease are linked to various adult diseases.
In order to prevent this, blood pressure reduction and prevention or treatment of vascular inflammation are important.
However, conventionally used therapeutic agents such as chemical vasoconstrictors cause side effects such as endothelial damage, hemolysis, acute toxicity or fish toxicity, acute nephritis or heart attack in a living body, and the production process is difficult and mass production is easy There was a problem that it was not possible.
Accordingly, the present applicant has discovered the present invention, which is effective for preventing, ameliorating or treating vascular diseases without using side effects by using natural products, having no toxicity even if taken for a long time.
The present invention uses red ginseng and lactic acid bacteria as materials, and briefly describes red ginseng and lactic acid bacteria.
Red ginseng (ginseng) ginseng (ginseng, Panax ginseng CA Meyer) refers to dried red ginseng steamed roots.
Important components of red ginseng include glycosides, panacen, polyacetylenic compounds, nitrogenous compounds, flavonoids, vitamins (B group), trace elements, enzymes, antioxidants, organic acids and amino acids .
Red ginseng has sedative and excitatory effects on the central nervous system and acts on the circulatory system to prevent hypertension and arteriosclerosis. In addition, it reduces the blood sugar level (blood sugar level), protects the liver, acts on the endocrine system and indirectly acts on sexual behavior (sexual behavior) and reproductive effect, and anti-inflammatory and anti- Tumor effect), radiation protection, skin protection and softening action.
In addition, red ginseng has been recognized as functional for improvement of blood flow through fatigue recovery, immunity enhancement, and inhibition of platelet aggregation.
Lactic acid bacteria are lactic acid bacteria, which ferment saccharides to obtain energy and produce bacteria that produce large amounts of lactic acid.
Lactobacillus , Lactococcus , Leuconostoc , Pediococcus, and Bifidobacterium are suitable for the definition of lactic acid bacteria. It is divided into two types, Lactococcus , Pediococcus and Leuconostoc , and Lactobacillus and Bifidobacterim . Gram stain is positive. Both develop well in an environment of low oxygen and produce lactic acid from various sugars. Many of them show tolerance to acids, and their nutritional requirements are very complex. They require many kinds of amino acids and vitamins in addition to sugars. Some bacteria can not grow unless added with trace nutrients depending on the strain.
Lactobacillus is a typical lactobacillus which is used in various fermented foods and also has an important relation with human and animal health as a superficial glutinous fungus.
Meanwhile, Korean Patent Publication No. 10-1392204 discloses a composition for preventing or treating vascular diseases containing herbal extracts of red ginseng, angelica gingiva, dermis, and green tea in the prior art related to the present invention.
More particularly, the present invention provides a composition for preventing or treating vascular diseases selected from arteriosclerosis, angina pectoris, myocardial infarction, ischemic heart disease, cerebral infarction and stroke, which comprises extracts of herbal medicine of red ginseng, .
Korean Patent Registration No. 10-1517836 discloses a composition for preventing, ameliorating or treating atherosclerosis containing an effective component of a complex of red ginseng.
The above red ginseng complex comprises 300 parts by weight of a red ginseng extract, 100 parts by weight of a ginseng extract, 100 parts by weight of a red ginseng extract, a red ginseng extract, And 100 parts by weight of the leaf extract, wherein the composition has an antioxidative effect in the body, an anti-inflammatory effect in the body, an effect of reducing vascular CRP (C reactive protein), a vascular smooth muscle (Vascular cell adhesion molecule), ICAM-1 (intercellular adhesion molecule) and E-selection, and an increase in intravascular PPAR-gamma Or a pharmaceutically acceptable salt thereof. The present invention also relates to a health functional food composition for preventing or ameliorating atherosclerosis.
In the thesis, the dissertation of Professor Dong Sung Medical Dept. of Dongseo Medical School, Kyung Hee University, "The study on the hematological index that affects blood vessel changes and blood vessels according to administration of red ginseng" It is said that the effect is effective.
However, the above-mentioned prior arts contain only red ginseng among the materials of the present invention, and there is a problem that the synergistic effect of mixed germination of red ginseng and lactic acid bacteria can not be known.
A problem to be solved by the present invention is to provide a composition containing a fermented product fermented by mixing red ginseng and lactic acid bacteria as an active ingredient, for preventing, improving or treating vascular diseases.
The present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide a method for reducing blood pressure, efficacy for alleviating vascular lesions, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule- ET-1 < / RTI > (endothelin-1).
The present invention aims to solve the technical problem by providing a composition for preventing, ameliorating or treating vascular diseases containing fermented product fermented by mixing red ginseng and lactic acid bacteria as an effective ingredient.
The present invention relates to a method for reducing blood pressure and reducing vascular lesions in a high-fructose diet rat model, and a method for inhibiting angiotensin-converting enzyme (ICAM-1), vascular cell adhesion molecule- -1 < / RTI > expression in a mammal, including a mammal, a human, a mammal, and a human.
The composition according to the present invention lowers blood pressure in a hyperfumine diet rat model, alleviates vascular lesions such as hypertrophy of the intravascular smooth muscle and abnormal hypertrophy of endothelial cells, and inhibits intercellular adhesion molecule-1 (ICAM-1), VCAM- 1 (vascular cell adhesion molecule-1) and ET-1 (endothelin-1).
FIG. 1 is a graph showing changes in blood pressure according to a sample treatment in a high-fructose diet rat model.
FIG. 2 is a photograph showing blood vessel atherogenesis of the thoracic aorta according to the sample treatment in a high fructose diet rat model.
FIG. 3 is a graph showing changes in the length of the intima-media of the thoracic aorta according to the sample treatment in a hyperglycemic rat model.
FIG. 4 is a photograph and a graph showing the degree of expression of ICAM-1 according to a sample treatment in a high-fructose diet rat model.
FIG. 5 is a photograph and a graph showing the degree of expression of VCAM-1 according to a sample treatment in a high-fructose diet rat model.
FIG. 6 is a photograph and a graph showing the degree of expression of ET-1 according to the sample treatment in a high-fructose diet rat model.
The terms and words used in the present specification and claims should not be construed as limited to ordinary or dictionary terms and the inventor may properly define the concept of the term in order to best describe its invention It should be construed as meaning and concept consistent with the technical idea of the present invention.
Therefore, the experimental examples and the reference examples described in the present specification are merely the most preferred embodiments of the present invention and are not intended to represent all of the technical ideas of the present invention. Therefore, various equivalents and variations Examples should be understood.
Example
1. Composition containing red ginseng and lactic acid bacteria
The composition for preventing, ameliorating or treating vascular diseases according to the present invention comprises a fermented product fermented by mixing red ginseng and lactic acid bacteria as an active ingredient. The preparation process will be described below.
1) Red ginseng and lactic acid bacteria are mixed.
At this time, red ginseng may be used in the unprocessed state, or may be ground. In addition, red ginseng can be sterilized before fermentation by mixing with lactic acid bacteria.
The lactic acid bacteria can use the Lactobacillus bacteria (Lactobacillus), flow Pocono stock (Leuconostoc), Enterococcus (Enterococcus), Bifidobacterium (Bifidobacterium) and any one or more lactic acid bacteria selected from Streptococcus (Streptococcus).
The mixing ratio of red ginseng and lactic acid bacteria may be 0.1 to 50 parts by weight of lactic acid bacterium based on 100 parts by weight of red ginseng.
2) Ferment the mixture.
Fermentation of the mixture may be carried out at 30 to 50 ° C for 12 to 72 hours, respectively, and may be fermented with stirring.
Depending on the design conditions, the fermentation temperature and fermentation time can be controlled and an environment suitable for the fermentation of the fermentation strain is sufficient.
The fermentation product fermented by the above-mentioned lactic acid bacteria increases the extraction efficiency of the medicinal component and facilitates absorption in the body.
3) Extract the fermented product.
The fermentation product is extracted to prepare a composition according to the present invention.
Various extraction methods such as a solvent extraction method, a steam distillation method, a carbon dioxide supercritical extraction method, a steam distillation method, a microwave process extraction method and a percolation extraction method may be used as the extraction method, and a solvent extraction method may be preferably used.
In solvent extraction, extraction solvents and various solvents may be used.
Extractable solvents include water, ethanol, methanol, fatty oil, glycerin, mayo, propylene glycol, ether, chloroform, petroleum ether, hexane, benzene, methylene chloride, ethyl acetate, acetone, butanol and isopropanol. Depending on the extraction temperature, the extraction time, the amount of the solvent, and the method of treating the residual components, the treatment can be performed.
In the composition according to the present invention, the concentration of the extract of the fermented product mixed with fermented red ginseng and lactic acid bacteria may be 20 to 300 mg / kg per day on the basis of the high fructose diet rat model, preferably 250 mg / kg per day Lt; / RTI >
In addition to the processes described above, filtration, concentration, extraction, and the like may be repeatedly performed in accordance with design conditions, and other processes such as fermentation and freezing may be performed before and after each process.
Reference Example
1. Preparation of experimental model
1) High fructose diet rat model
A high fructose diet rat model was used to induce vascular disease.
A high fructose diet rat model was constructed by administering Research Diets high fructose diet for about 9 weeks, and the feed contained 60% fructos.
2) Sample administration
The extracts of red ginseng and lactic acid bacterium were prepared according to the above Example 1, 250 mg / kg per day, and the red ginseng extract was prepared as a comparative group and administered at a dose of 250 mg / kg per day.
Were administered to the rats simultaneously with the high fructose diet for 9 weeks each.
Hypertension is seen in most people with metabolic syndrome, which is one of the most dangerous factors in heart disease and cerebrovascular disease.
Therefore, the drug used as a positive control was the AT type II receptor antagonist Losartan, which is used in clinical practice as an angiotensin receptor blocker (ARB), and was administered at a dose of 30 mg / kg per day for 9 weeks to the high fructose diet At the same time, they were administered to the rats.
Experimental Example
1. Measurement of blood pressure change
1-1. Experimental course
Systolic mean blood pressure was measured in rat tail artery using automatic sphygmotonography (Mutomachi Kikai, Tokyo, Japan). Blood pressure was measured at least 8 times for each subject, and 5 measurements within 5 mmHg were used as mean values.
1-2. Experiment result
FIG. 1 is a graph showing changes in blood pressure according to a sample treatment in a high-fructose diet rat model.
There was no significant difference between the groups in terms of blood pressure before and after high fructose diet and drug administration.
However, blood pressure was measured after the initiation of high fructose diet and drug administration (3 weeks). As a result, blood pressure was increased in the rest of the control group.
In addition, blood pressure at 6 and 9 weeks showed a significant difference in the control and high fructose groups. In the group treated with red ginseng extract and red ginseng + lactic acid bacterium, blood pressure was significantly decreased compared with the high fructose group I could confirm.
Experimental Example
2. Check for vascular lesions
2-1. Experimental course
The extracted thoracic aortic tissue was fixed in 10% formalin (pH 7.4) for 3 days, and the remaining formalin was removed.
Dehydrated in the order of increasing concentration from 50% alcohol to 100% alcohol, substituted with xylen, embedded in paraffin, and embedded.
The prepared paraffin blocks were attached to the slides after 4-5 μm separation using a microtome (Thermo Electron Corporation, Pittsburg, Pa.).
Hematoxylin-eosin staining was performed to observe the morphologic changes of the thoracic aorta, and the thoracic aorta was photographed after observing the thoracic aorta at 400-fold visual field under an optical microscope.
2-2. Experiment result
FIG. 2 is a photograph showing blood vessel atherogenesis of the thoracic aorta according to the sample treatment in a hyperglycemic-type rat model, and FIG. 3 is a graph showing changes in the intima-media thickness of the thoracic aorta according to the sample treatment in a hyperglycemic- to be.
As a result, vascular atheromatosis was not observed in the thoracic aorta of the vascular lesion metabolic syndrome model using a high-fructose diet rat model, but endothelial tissue was damaged by the length of the intima-media, indicating that the thickening of smooth muscle and abnormal endothelial cells Hypertrophy, that is, early atherosclerosis.
In the group treated with red ginseng extract and red ginseng + lactic acid bacterium extract, the degree of vascular injury was decreased.
Experimental Example
3. Expression of vascular disease-related factors
3-1. Experimental course
1) Expression of vascular inflammatory factor
Immunohistochemistry staining was performed to measure the expression levels of ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), which are vascular inflammatory factors, Were photographed after observing at 400x field of view.
Plasma was also centrifuged at 3000 rpm for 20 minutes and then measured using an ELISA kit.
2) Measurement of expression of vasoconstrictor
The expression level of ET-1 (endothelin-1), a vasoconstrictor, was measured in order to investigate the changes in vasoconstriction in the thoracic aorta. The experimental procedure was the same as that in 1) of 3-1.
3-2. Experiment result
FIG. 4 is a photograph and a graph showing the degree of expression of ICAM-1 according to a sample treatment in a high-fructose diet rat model, and FIG. 5 is a graph showing the degree of expression of VCAM-1 in the high- And graphs.
ICAM-1 (intercellular adhesion molecule-1), also called CD (antigen), is a transmembrane protein with a molecular weight of 90,000. (IgSF), which is widely distributed in vascular endothelial cells, epithelial cells, hematopoietic cells, and the like, and mainly binds to leucocyte β2 integrin LFA-1 in a divalent metal cation-dependent manner.
Expression of ICAM-1 plays an important role in the inflammatory state by inducing stimulation of inflammatory cytokines such as TNF-α, active oxygen, leukocyte extravasation and activation of T cells by antigen presenting cells do.
In addition, VCAM-1 (vascular cell adhesion molecule-1) is a cell adhesion molecule that induces expression at the peak of 24 to 48 hours by inflammatory cytokinins or lipopolysaccharides such as
In vivo, activated vascular endothelial cells appear in inflamed areas, and are expressed in stromal cells of the thymus and bone marrow, dendritic cells in the center of the spleen (embryo), and skeletal muscle. It also binds to integrin α4β1, is involved in lymphocyte infiltration into inflammatory sites, adhesion of stem cells and stromal cells, and root canal formation.
The expression of ICAM-1 and VCAM-1 was increased in the high fructose group compared to the control group. This suggests that the high fructose diet promotes vascular inflammation damage.
However, the levels of ICAM-1 and VCAM-1 were significantly decreased in the Losartan group, the red ginseng extract group, and the red ginseng + lactic acid bomb extract group, compared with the high fructose group.
FIG. 6 is a photograph and a graph showing the degree of expression of ET-1 according to the sample treatment in a high-fructose diet rat model.
ET-1 (endothelin-1) is a vasoconstrictor, a protein that contracts blood vessels, increases blood pressure, and reduces oxygen supply to the heart.
Increased ET-1 increases the risk of heart disease (Psychosomatic Medicine 2002; 64: 707-713).
In the high fructose group, the expression of ET-1 was significantly higher than that of the control group, but the expression level of ET-1 was higher in the group treated with the red ginseng extract and red ginseng + lactic acid bacterium Respectively.
Claims (5)
The concentration of the extract extracted from the fermented product was 250 mg / kg per day on the basis of a high fructose diet rat model,
Wherein the vascular disease is hypertension, coronary artery disease, atherosclerosis or hyperlipidemia.
The composition reduces the blood pressure, reduces the hypertrophy of the intravascular smooth muscle and the abnormal hypertrophy of the endothelial cells in the hyperfumated diabetic rat model, and inhibits intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 ) And ET-1 (endothelin-1) in a mammal, including a human.
The concentration of the extract extracted from the fermented product was 250 mg / kg per day on the basis of a high fructose diet rat model,
Wherein said vascular disease is hypertension, coronary artery disease, atherosclerosis or hyperlipidemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150077729A KR101792875B1 (en) | 2015-06-02 | 2015-06-02 | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150077729A KR101792875B1 (en) | 2015-06-02 | 2015-06-02 | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160141986A KR20160141986A (en) | 2016-12-12 |
| KR101792875B1 true KR101792875B1 (en) | 2017-11-01 |
Family
ID=57574319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150077729A KR101792875B1 (en) | 2015-06-02 | 2015-06-02 | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101792875B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102175436B1 (en) * | 2018-09-03 | 2020-11-06 | 연세대학교 산학협력단 | A pharmaceutical composition for functional recovery of cord blood endothelial progenitor cells and treat of preeclampsia by Ginseng including Rg3 |
| KR102155057B1 (en) * | 2019-04-05 | 2020-09-11 | 조권석 | Food Composition for blood circulation and preventing blood vessel disease Comprising red ginseng and nitric oxide solution and its manufacturing method |
| KR102218529B1 (en) * | 2019-07-17 | 2021-02-22 | 주식회사 리바이오 | Composition comprising Salvia miltiorrhiza and red ginseng biotransformation extract for improving, preventing and treating of cardiovascular disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101392204B1 (en) | 2012-02-27 | 2014-05-08 | 충남대학교산학협력단 | Composition comprising herbal extract of red ginseng, Angelicae gigantis Radix, citrus peel and green tea leaves for treating or preventing vascular diseases |
| KR101517836B1 (en) | 2013-06-05 | 2015-05-07 | 재단법인 진안홍삼연구소 | A composition for the treatment of atherosclerosis comprising the red ginseng complex |
-
2015
- 2015-06-02 KR KR1020150077729A patent/KR101792875B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160141986A (en) | 2016-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9439874B2 (en) | Food composition for nourishing, maintaining and cultivating a variety of stem cells and a method for manufacturing the same | |
| KR101792875B1 (en) | A composition comprising red ginseng and lactic acid bacteria for preventing, improving or treating vascular disease | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| WO2019153816A1 (en) | Application of chaenomeles speciosa betulinic acid in preparation of anti-hypertension myocardial fibrosis medicines | |
| KR20210133909A (en) | Composition for prevention or treatment of bone disease or menopause related disease comprising Salicornia spp. extract | |
| CN111356468A (en) | Composition for preventing or treating fibrotic disease comprising extract of Rhus toxicodendron | |
| KR101501233B1 (en) | Pharmaceutical composition or health food containing black tea ethanol solution extracts which is effective for reducing body weight and body fats or preventing or treating lipid related metabolic disease | |
| WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
| JP6638161B2 (en) | Food and beverage composition for inhibiting fat accumulation, food and beverage composition for preventing or treating fatty liver, and food and beverage composition for inhibiting fatty acid synthase | |
| KR20160123130A (en) | Composition comprising Chrisanthemum indicum extract or fraction for treating, improving or preventing obesity or obesity-related disease | |
| KR20180101460A (en) | Uses of Sisotanke Tubulosa Extract and Isoquateroside in the Protection of Muscle | |
| CN109662967A (en) | A kind of antidepressant and application thereof | |
| CN101711793B (en) | Medicinal composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| EP4248964A1 (en) | Pharmaceutical composition for treating sepsis, and use thereof | |
| KR20220117115A (en) | Pharmaceutical composition for preventing or treating muscle atrophy or cachexia comprising gintonin | |
| TWI677345B (en) | Use of extract of artocarpus heterophyllus white core for regulating expression of cfos gene, csf1r gene, rank gene, syk gene, trap gene, apa1 gene, abca1 gene, il-6 gene, vcam1 gene, casp8 gene, ddc gene and asmtl protein gene, and improving menopausal | |
| KR20180042920A (en) | Extracts from red bean shell having anti obesity and Compositions comprising the same as an active ingredient | |
| KR20160142430A (en) | A composition comprising fermented extracts of red ginseng and rubus coreanus for preventing, improving or treating vascular disease | |
| CN114588212A (en) | New use of traditional Chinese medicine water lettuce for resisting heart failure | |
| Cui et al. | Antitumor and immunoregulation effects and mechanism of n-butanol fraction from Zanthoxylum avicennae in H22 mice | |
| US20200330538A1 (en) | Novel use of combination or composition of panax notoginseng and aspirin | |
| KR101864121B1 (en) | Composition comprising extract of Acanthopanax koreanum for preventing or treating of vascular disease | |
| KR20150105561A (en) | Pharmaceutical composition for preventing or treating bone disease comprising Hovenia dulcis Thunb extract | |
| KR102160627B1 (en) | Pharmaceutical composition for preventing or treating bone disease comprising extracts of branches of Hovenia dulcis Thunb | |
| WO2022178967A1 (en) | Pharmaceutical composition of forskolin-isoforskolin and pentacyclic triterpenoid compound, and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |